Mergers & Acquisitions
By The Online Investor Staff, updated Sun., Jan. 29, 6:21 PM
| This Slide: #58 of 100 |
Slide #58. Calyxt, Inc. — Cibus
Acquirer:
Calyxt, Inc. (NASDAQ:CLXT)
Acquiree:
Cibus
Details:
Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. The merger will create a new industry-leading company that combines the two pioneers in agriculture-based gene editing and establishes one of the world's most sophisticated facilities for trait development and next-generation plant breeding.
Calyxt is a plant-based synthetic biology company that utilizes its proprietary PlantSpring™ technology platform to engineer plant metabolism to produce plant-based chemistries for use in customers' materials and products. Co. is focused on developing these synthetic biology solutions for customers in differentiated end markets, including the cosmeceutical, nutraceutical, and pharmaceutical industries. Co. also out-licenses elements of the PlantSpring technology platform and may selectively develop products for customers in agriculture. Co.'s product, an improved digestibility alfalfa, was developed with and licensed to S&W Seed Company.
Open the CLXT Page at The Online Investor »
|
|||||||||||||||||||||
Open the CLXT Page at The Online Investor (in a new window) »
 Free CLXT Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Hold (2.00 out of 4) 0th percentile
(ranked lower than approx. 100% of all stocks covered)
Analysts' Target Price: CLXT Stock Forecast Based on Zacks ABR data; powered by Xignite |
